Adverse reactions occurring in at least 20% of patients receiving sotorasib/panitumumab were rash, dry skin, diarrhea, stomatitis, fatigue, and musculoskeletal pain. Common grade 3-4 laboratory ...
[22] In the study conducted by Lenz et al, the severity of rash was strongly related to both ORR and OS. Forty out of 311 patients (13%) who developed skin rash experienced a PR, whereas none of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback